Irinotecan, Gemcitabine and Radiation Therapy for Pancreatic Cancer

Sponsor
Rambam Health Care Campus
Study ID
NCT00192712
Phase
PHASE2/PHASE3
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The study hypothesis is that chemoradiation based on 2 drugs will improve local control and long-term survival in patients with locally advanced pancreatic cancer. That is why gemcitabine and irinotecan are combined in an induction phase of 2 months and then this IrinoGem combination is given for 3 more cycles, in reduced doses,concurently with irradiation.

Key Dates

Start date
Nov 30, 2002
Status verified
Sep 2010
Completion
Sep 30, 2010

Study Design

Enrollment
20 participants
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

time to treatment failure

Related Studies